Chemed (CHE) Q4 2025 earnings review
VITAS Escapes the Cap, But Roto-Rooter Springs a Major Leak
Chemed's Q4 paints a tale of two vastly different trajectories. Consolidated revenue flatlined at $639.3M, masking a severe divergence beneath the surface. The regulatory dark cloud over VITAS has officially lifted: management successfully mitigated the Florida Medicare Cap, dropping projected 2026 cap liabilities from $27.2M to a highly manageable $9.5M. However, this massive win was entirely offset by a sudden collapse at Roto-Rooter, where revenue reversed into a 3.7% contraction and adjusted EBITDA margins plunged 477 basis points. Despite the current bottom-line pain (Adjusted EPS down 6.0%), management's 2026 guidance points to a robust recovery, albeit one heavily back-loaded into the second half of the year.
🐂 Bull Case
The defensive patient mix-shift strategy worked. With zero Florida Medicare Cap recorded in Q4, VITAS is free to normalize its patient mix toward longer-stay, higher-margin patients in 2026.
Management took advantage of the stock's weakness, repurchasing a massive 400,000 shares for $174.6M in Q4 alone—a sharp acceleration from the mere 50,000 to 75,000 shares repurchased in earlier quarters.
🐻 Bear Case
In Q3, management claimed Roto-Rooter was stabilizing. Q4 proved otherwise. Revenue reversed from positive growth to a 3.7% decline, and adjusted EBITDA collapsed 21.1% YoY.
Management admits the 2026 earnings recovery is heavily weighted to the second half (55% of net income). Any further macro softening or failure to fix Roto-Rooter's lead generation will derail the $23.25-$24.25 EPS target.
⚖️ Verdict: ⚪
Neutral. The VITAS regulatory win is a massive structural relief, but Roto-Rooter's margin and volume deterioration requires immediate proof of stabilization before buying into the H2-weighted 2026 guidance.
Key Themes
VITAS Florida Medicare Cap Mitigation Successful
The dominant headwind for Chemed throughout 2025 has been defeated. After racking up $27.2M in Medicare Cap billing limitations for calendar 2025, the deliberate strategy to increase hospital-based, short-stay admissions has rebalanced the portfolio. Q4 saw $0 in Florida combined program cap limitations. This frees VITAS to abandon defensive operating postures in 2026, dropping the projected full-year cap to just $9.5M.
Roto-Rooter SG&A Spikes While Revenue Falls
A severe negative operating leverage dynamic has emerged at Roto-Rooter. Despite revenue reversing to a 3.7% decline, SG&A expenses surged 10.5% YoY to $63.2M. This complete mismatch collapsed the adjusted EBITDA margin from 26.3% a year ago down to 21.5%. Management blames elevated expenses needed to 'fund revenue growth,' but the top-line results show those investments are currently yielding negative returns.
Paid Lead Generation Shift Pressures Margins
The macro environment remains tough for Roto-Rooter. Prior quarters revealed a structural decline in 'natural' (unpaid) Google leads, forcing Roto-Rooter into an aggressive and costly Paid Search strategy. While management previously framed this as 'stabilizing' the business, Q4's residential revenue drop of 3.1% indicates that consumer macro caution is overpowering the expensive marketing push.
VITAS Core Admissions Remain Resilient
Despite the intentional mix-shift disruptions over the past year, VITAS continues to capture share. Q4 total admissions accelerated to 6.0% growth (up from 5.6% in Q3), and Average Daily Census grew 1.3%. With a geographically weighted average Medicare rate increase of 2.2%, the core engine of VITAS remains highly stable.
Delayed Financial Impact of Patient Mix Normalization
While the Florida cap issue is solved, the positive narrative contradicts the near-term financials. Management explicitly warned that shifting back to a favorable balance of longer-stay patients will not instantly boost margins. The financial benefit of admitting these patients lags by 'roughly a fiscal quarter post-admission,' contributing to the tepid H1 2026 outlook.
Other KPIs
Decelerating. Net cash provided by operating activities dropped 7.0% from $417.5M in FY24. This reflects the pressure from Roto-Rooter's margin compression and the $27.2M VITAS cap penalty throughout the year, offset slightly by lower inventory levels.
Decelerating. Revenue from independent contractors declined 2.8% YoY, an improvement from the 4.7% drop in Q3, but still representing a persistent structural drag on the Roto-Rooter segment's overall recovery.
Stable. High acuity days-of-care declined 32 basis points YoY. This lower-acuity mix negatively impacted revenue growth by 143 basis points in the quarter, largely as a result of the ongoing (and now successfully completed) defensive cap-management strategy.
Guidance
Accelerating. The midpoint of $23.75 represents roughly a 10% rebound from FY25's $21.55. However, the company noted this is heavily back-half weighted (55%), requiring investors to look past a weaker H1.
Accelerating from Q4's 1.9% growth, supported by a projected 3.5% to 4.0% increase in Average Daily Census. Adjusted EBITDA margin is guided to 17.5% - 18.0%, reflecting the transition back to normalized patient lengths of stay.
Reversing the -3.7% contraction seen in Q4. However, achieving this requires the paid internet marketing investments to finally translate into sustained volume growth against a cautious consumer backdrop.
Improving sequentially from Q4's dismal 21.5%, but remaining severely depressed compared to the company's historical long-term target of 25%-26%, confirming that higher SG&A/paid lead costs are a structural, multi-year headwind.
Key Questions
Roto-Rooter SG&A Efficacy
SG&A expenses at Roto-Rooter surged 10.5% in Q4 while revenues fell 3.7%. If the shift to Paid Google Leads is capturing market share from PE-backed competitors as previously claimed, why is it failing to translate into top-line growth?
VITAS Patient Mix Normalization Timeline
With the Florida Cap successfully mitigated, exactly how rapidly do you expect to transition away from the heavy mix of short-stay, hospital-based admissions, and what is the specific margin bridge to get back to the 19%+ levels seen in early 2024?
H1 Margin Trough at Roto-Rooter
You noted elevated expenses in H1 2026 for Roto-Rooter to fund 'long-term margin improvement projects.' Could you detail these specific projects and clarify what the expected EBITDA margin trough will be in Q1/Q2 before the H2 recovery?